alexa Is HbA1c still the Gold Standard for Glycemic Control? | OMICS International
ISSN: 2475-3211
Journal of Diabetic Complications & Medicine

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Is HbA1c still the Gold Standard for Glycemic Control?

Vito Borzi*

Department of Internal Medicine, Azienda Ospedaliera, Universitaria Policlinico – Vittorio Emanuele, Catania, Italy

Corresponding Author:
Professor Vito Borzi
Department of Internal Medicine
Azienda Ospedaliera – Universitaria Policlinico – Vittorio Emanuele
Catania, Italy
Tel: +39 3386956220
E-mail: [email protected]

Received Date: February 27, 2017; Accepted Date: February 28, 2017; Published Date: March 07, 2017

Citation: Borzi V (2017) Is HbA1c still the Gold Standard for Glycemic Control?. J Diabetic Complications Med 2:e103. doi: 10.4172/2475-3211.1000e103

Copyright: © 2017 Borzi V. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Diabetic Complications & Medicine



Numerous intervention trials have shown that intensive glycemic control is effective in preventing microvascular complications in both type 1 and type 2 diabetes; whereas the reduction of macrovascular complications requires a much more prolonged treatment.

This led to the conclusion that diabetes was a cardiovascular disease diagnosed by hyperglycemia. It was reduced in this way the role of hyperglycemia, and especially of its intensive treatment, as a causal factor of cardiovascular complications [1].

Furthermore the demonstration that the hypertension and dyslipidaemias control was more effective than glycemic control has further strengthened this concept. In recent years, three large trials (ACCORD - ADVANCE -VADT) confirmed even the negative effects of tight glycemic control on cardiovascular risk in type 2 diabetes [2,3].

It must however be noted that in these studies the risk of hypoglycemia was significantly increased in the intensive care arm; and, as we know, hypoglycemia is independently associated with an increased risk of mortality and vascular complications.

One might therefore conclude that achieving good glycemic control to prevent cardiovascular complications could be useless, if not harmful. The HbA1c is currently the gold standard of glycemic control and is commonly used to evaluate the effectiveness of therapeutic treatment [4].

But the inadequacy of the use of HbA1c as the only indicator of glycemic control was recently highlighted by the Swedish national registry data of type 1 diabetes. Patients with HbA1c <6.9% were still at risk of death, for any cause or cardiovascular causes, which was two times greater than non-diabetic subjects.

And because in type 1 diabetes, obesity, hypertension and dyslipidemia have a marginal role, the increased mortality in well compensated subjects strengthens the view that HbA1c cannot be considered the only marker of a good glycemic control [5].

We should probably consider not hyperglycemia "in itself ", but the different types of hyperglycemia. The postprandial hyperglycemia could be an important independent risk factor, although still not demonstrated convincingly by evidence based medicine.

The alterations of endothelial dysfunction in post-prandial hyperglycemia could play an important role in the pathogenesis of cardiovascular complications. Furthermore it’s important not to forget that a good control of post-prandial blood glucose significantly contributes to the optimization of HbA1c [6].

Also the glucose variability can be a significant independent risk factor for cardiovascular complications, even in subjects without diabetes. More fluctuations of blood glucose may be more damaging than a single episode of hyperglycemia both acute and a chronic hyperglycemic state.

Furthermore, the glucose variability facilitates hypoglycemic episodes, which, as well known, constitute a cardiovascular risk factor. It has recently been demonstrated that hyperglycemia that follows to a hypoglycemic episode causes an impairment of ischemic preconditioning, aggravating the risk of vascular events, as well as in post-prandial hyperglycemia [7,8].

From the above it is clear that the HbA1c represents only one aspect of glycemic control and therefore cannot be the gold standard of diabetes treatment. Probably now we have to have a broader view of the problem.

Therefore diabetes management becomes more challenging and perhaps diabetologist should go back a little to be again "Expert in Glycemia", a term that had been banned in recent years. Indeed a modern approach to glycemic control must provide for the achievement of an optimal level of HbA1c, but with a postprandial hyperglycemia control, a reduction in glycemic variability and a desirable absence of hypoglycemia.

Nowadays it’s possible getting all this, thanks to the availability of better therapies and more effective instruments in the glucose monitoring. The incoming years will tell us whether this more complex view, but perhaps more physiological, will give us the desired results in terms of reduction in cardiovascular events.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 630
  • [From(publication date):
    September-2017 - Jun 24, 2018]
  • Breakdown by view type
  • HTML page views : 572
  • PDF downloads : 58

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7